ReviewSarcoma2015
Rhabdomyosarcoma: Advances in Molecular and Cellular Biology.
Review in Sarcoma, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 50 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
50 citing papers in PubMed, 102 citations in OpenAlex.
- Cutaneous metastases of alveolar rhabdomyosarcoma in a young adult.JAAD case reports · 2025Article
- Unwinding new therapeutic opportunities in rhabdomyosarcoma: the role of RNA helicase DDX5.Frontiers in cell and developmental biology · 2025Review
- DiPRO1 distinctly reprograms muscle and mesenchymal cancer cells.EMBO molecular medicine · 2024Article
- p160 nuclear receptor coactivator family members and their role in rare fusion‑driven neoplasms (Review).Oncology letters · 2024Review
- Practical Management of Adult Ultra-Rare Primary Retroperitoneal Soft Tissue Sarcoma: A Focus on Perivascular Epithelioid Tumours and Extraosseous Ewing Sarcoma.Current oncology (Toronto, Ont.) · 2023Review
- The mNature communications · 2023Article
- Quantitative proteomics identifies and validates urinary biomarkers of rhabdomyosarcoma in children.Clinical proteomics · 2023Article
- Identify potential driver genes for PAX-FOXO1 fusion-negative rhabdomyosarcoma through frequent gene co-expression network mining.Frontiers in oncology · 2023Article
- An Update on Circular RNA in Pediatric Cancers.Biomedicines · 2022Review
- Myogenetic Oligodeoxynucleotides as Anti-Nucleolin Aptamers Inhibit the Growth of Embryonal Rhabdomyosarcoma Cells.Biomedicines · 2022Article
- Anti‑oncogenic and pro‑myogenic action of the MKK6/p38/AKT axis induced by targeting MEK/ERK in embryonal rhabdomyosarcoma.Oncology reports · 2022Article
- Article
- Metastatic ethmoidal alveolar rhabdomyosarcoma presenting as a scalp nodule in an adult woman.JAAD case reports · 2022Article
- Article
- Emerging Roles ofFrontiers in genetics · 2022Review
- Radioresistance in rhabdomyosarcomas: Much more than a question of dose.Frontiers in oncology · 2022Review
- MCKAT: a multi-dimensional copy number variant kernel association test.BMC bioinformatics · 2021Article
- Bioinformatics prediction and experimental verification identify MAD2L1 and CCNB2 as diagnostic biomarkers of rhabdomyosarcoma.Cancer cell international · 2021Article
- SMCKAT, a Sequential Multi-Dimensional CNV Kernel-Based Association Test.Life (Basel, Switzerland) · 2021Article
- Repurposing proscillaridin A in combination with decitabine against embryonal rhabdomyosarcoma RD cells.Cancer chemotherapy and pharmacology · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 4 institutions in 2 countries.
Funding
Abstract
Rhabdomyosarcoma (RMS) is the most common soft tissue malignancy in childhood and adolescence. The two major histological subtypes of RMS are alveolar RMS, driven by the fusion protein PAX3-FKHR or PAX7-FKHR, and embryonic RMS, which is usually genetically heterogeneous. The prognosis of RMS has improved in the past several decades due to multidisciplinary care. However, in recent years, the treatment of patients with metastatic or refractory RMS has reached a plateau. Thus, to improve the survival rate of RMS patients and their overall well-being, further understanding of the molecular and cellular biology of RMS and identification of novel therapeutic targets are imperative. In this review, we describe the most recent discoveries in the molecular and cellular biology of RMS, including alterations in oncogenic pathways, miRNA (miR), in vivo models, stem cells, and important signal transduction cascades implicated in the development and progression of RMS. Furthermore, we discuss novel potential targeted therapies that may improve the current treatment of RMS.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.